SYHA1813 , A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70166 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Zhuang Kang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Glioma, Neoplasm Recurrence, Local, Brain Neoplasms, Receptors, Vascular Endothelial Growth Factor. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Runshi Medical Technology Co. Ltd, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813 , a dual inhibitor of VEGFR and CSF1R , in patients with recurrent high‐grade gliomas.
Methods
Eligible patients (aged ≥ 18) with histologically or cytologically confirmed recurrent high‐grade gliomas were included. Patients were administered different doses of SYHA1813 daily to assess its safety and initial efficacy.
Results
Sixty‐four individuals with high‐grade gliomas were enrolled. Treatment‐related adverse events (TRAEs) were reported in 92.2% of the patients, with 40.6% experiencing grade 3 or higher TRAEs. No grade 5 TRAE was reported. The overall objective response rate (ORR) and disease control rate (DCR) were 18.8% (95% confidence interval [CI], 10.1–30.5) and 51.6% (95% CI, 38.7–64.3), respectively. With a median follow‐up duration of 9.5 months, the median progression‐free survival (PFS) was 2.8 months (95% CI, 2.3–4.2) with PFS‐6 of 22.5% (95% CI, 11.8–35.4) and the median OS was 15.1 months (95% CI, 10.2–NE) with OS‐12 of 63.3% (95% CI, 49.3–74.4). Among the 38 patients with glioblastoma, the ORR was 18.4% (95% CI, 7.7–34.3), with a DCR of 52.6% (95% CI, 35.8–69.0). The median PFS and OS were 4.1 months (95% CI, 2.3–5.3) and 13.0 months (95% CI, 9.1–NE), respectively. SYHA1813 was detected in cerebrospinal fluid samples and the drug concentration to plasma free drug concentration ratio was 0.30–1.27.
Interpretation
SYHA1813 exhibits encouraging anti‐tumor activity with a manageable safety profile for the treatment of recurrent high‐grade gliomas, especially glioblastoma. Trial Registration chictr.org.cn (ChiCTR2100045380)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Neurosurgery, Tangdu Hospital, Air Force Military Medical University, Xi'an, China.
- Department of Neurosurgery, Hubei General Hospital, Renmin Hospital of Wuhan University, Wuhan, China.
- Department of Oncology, Hubei General Hospital, Renmin Hospital of Wuhan University, Wuhan, China.
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Qianxue Chen, Wenbin Li
Förderung
- Shanghai Runshi Medical Technology Co. Ltd
- National Natural Science Foundation of China
Zitieren
APA
Kang, Z., Li, S., Wang, L., Chen, Q., Hu, W., Lei, T., Mao, Y., Zhang, J., Xiang, X., Wang, Q., He, Z., Sun, T., Wang, Y., Huang, M., Zhang, R., Chen, F., & Li, W. (2025). SYHA1813 , A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70166
Vancouver
Kang Z, Li S, Wang L, Chen Q, Hu W, Lei T, et al. SYHA1813 , A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70166
BibTeX
@article{Kang2025,
author = {Kang, Zhuang and Li, Shenglan and Wang, Liang and Chen, Qianxue and Hu, Weiguo and Lei, Ting and Mao, Ying and Zhang, Jing and Xiang, Xiaojun and Wang, Qiming and He, Zhengwen and Sun, Tao and Wang, Yulei and Huang, Mengqian and Zhang, Rong and Chen, Feng and Li, Wenbin},
title = {SYHA1813 , A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70166}
}
EUVIMED